Le Lézard
Classified in: Health
Subjects: WOM, PSF, CFG, DEI

Public advisory - Unauthorized drugs for abortion and emergency contraception sold illegally on "Dr. Pooja" websites


OTTAWA, ON, May 16, 2023 /CNW/ - 

Summary
Affected products
Issue

Health Canada is warning consumers not to buy unauthorized heath products to terminate or prevent pregnancy as they may pose serious health risks. Health Canada is aware (link available in French only) of two "Dr. Pooja" websites (https://www.drpoojaclinic.ca/ and http://drpoojacliniccynaecologist.com/) selling unauthorized prescription drugs for medical abortion labelled to contain mifepristone and misoprostol, and unauthorized over-the-counter drugs for emergency contraception labelled to contain levonorgestrel.

Selling unauthorized health products in Canada is illegal, and Health Canada will do everything it can to stop this activity. Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks. For example, they may be ineffective, expired, mislabeled, subject to recalls, or counterfeit versions of authorized products. Unauthorized drugs may have no active ingredients, the wrong ingredients, or dangerous additives such as prescription drugs not listed on the label.

Health Canada has directed the websites to stop selling unauthorized health products and is working to have the websites removed. Health Canada will take further action as necessary to protect the health and safety of people in Canada.

What you should do
Background

Unauthorized prescription drugs labelled to contain mifepristone and misoprostol: Mifepristone and misoprostol are prescription drug ingredients taken in sequence for the medical termination of a pregnancy. For safety, it is very important that patients have close medical supervision, guidance and care. The use of mifepristone and misoprostol is not suitable to terminate all pregnancies. For example, the drugs should not be used by people who are more than nine weeks (63 days) pregnant, who have a pregnancy outside the uterus (ectopic pregnancy), who have an intra-uterine contraceptive device, who have bleeding disorders or who are on a blood thinner therapy, who are on long-term corticosteroid therapy, who have uncontrolled asthma or who are allergic to mifepristone or misoprostol.

There is an authorized mifepristone and misoprostol combination product available in Canada, sold under the brand name Mifegymiso. Health Canada has put in place several safeguards for its safe and effective use, including access to emergency medical care and scheduled follow-up care. People who take unauthorized drugs without proper medical supervision are at an increased risk of severe infection (that could be fatal), prolonged heavy bleeding, serious skin reactions and birth defects (if the pregnancy is not successfully terminated).

Unauthorized emergency contraceptive labelled to contain levonorgestrel: Levonorgestrel is a non-prescription drug used as an emergency contraceptive to prevent pregnancy within 72 hours of known or suspected contraceptive failure or unprotected sex, when sold as a single ingredient oral dose containing no more than 1.5 milligrams. Unauthorized emergency contraceptives labelled to contain levonorgestrel may be ineffective and may not prevent pregnancy as expected. The drug should not be taken by those allergic to levonorgestrel, or by those who are, or who suspect they are pregnant. For patients with undiagnosed abnormal vaginal bleeding, a pregnancy test should be performed before taking levonorgestrel. Levonorgestrel as an emergency contraceptive does not induce abortion and should not be taken by pregnant women as it will not be effective. There are authorized levonorgestrel emergency contraceptive products available in Canada.

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 22:36
The global drug discovery outsourcing market  size is estimated to grow by USD 1.79 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  7.44%  during the forecast period. ...

at 22:30
On or around February 6, 2024, Hypertension-Nephrology Associates, P.C. ("the Practice") became aware it was the target of an extortion attack when an extortion note was found on its computer system. Upon discovery of the extortion note, the Practice...

at 22:17
Dr. Scott McMahon of Whole World Health Care is happy to announce the 2024 annual Surviving Mold-CIRSx Conference, set to be held May 16-19, 2024 at the Hyatt Regency, located at 2615 Preston Road in Frisco, Texas, a city near Dallas. CIRSx was...

at 20:16
PDS Health®, a leading U.S. provider of integrated healthcare support services, proudly announces its recognition as one of The Civic 50 honorees of 2024 by Points of Light, the world's largest nonprofit dedicated to accelerating people-powered...

at 20:12
Note: All times local Quebec City, Quebec 9:30 a.m. The Prime Minister will take part in an historic announcement about the Québec Bridge. The Minister of Public Services and Procurement, Jean-Yves Duclos, and the Minister of Transport and Quebec...

at 19:35
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for...



News published on and distributed by: